Equities Analysts Issue Forecasts for ENLV Q1 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Enlivex Therapeutics in a research note issued to investors on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.02) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at ($0.02) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($0.09) EPS.

ENLV has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. Wall Street Zen cut Enlivex Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $16.50.

Enlivex Therapeutics Price Performance

Shares of Enlivex Therapeutics stock opened at $0.93 on Wednesday. The business has a 50-day moving average of $1.08 and a 200 day moving average of $1.02. Enlivex Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.10. The stock has a market capitalization of $221.50 million, a price-to-earnings ratio of -1.70 and a beta of 1.68.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. HRT Financial LP lifted its stake in Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after acquiring an additional 135,198 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Enlivex Therapeutics by 99.4% in the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after acquiring an additional 156,336 shares during the last quarter. Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after acquiring an additional 67,886 shares during the last quarter. Invesco Ltd. purchased a new position in Enlivex Therapeutics in the fourth quarter worth approximately $43,000. Finally, XTX Topco Ltd lifted its stake in Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after acquiring an additional 19,132 shares during the last quarter. Hedge funds and other institutional investors own 1.02% of the company’s stock.

More Enlivex Therapeutics News

Here are the key news stories impacting Enlivex Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target on ENLV to $20 and maintained a Buy rating — a very bullish signal that highlights the firm’s long-term confidence and may attract momentum/coverage-driven buying. Benzinga Price Target Raise
• Positive Sentiment: Ondo Finance launched ENLVon, a tokenized representation of Enlivex ordinary shares on its Global Markets platform — this can increase liquidity, fractional ownership, and access to new investor pools, which is typically viewed positively for otherwise thinly traded small-cap stocks. Ondo Tokenization (GlobeNewswire) Ondo Tokenization (Business Insider)
• Neutral Sentiment: HC Wainwright published quarterly and FY2027 EPS projections (mostly negative EPS of ~$0.02 per quarter and FY -$0.09) alongside its $20 target — useful for modeling but consistent with a developmental-stage biotech that is not yet profitable. HC Wainwright Estimates (MarketBeat)

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.